Abstract
Acute Myeloid Leukemia (AML) with FLT3 (FMS-like Tyrosine Kinase 3) mutations poses a significant challenge in oncology. This paper explores the potential of a combined treatment approach involving CRISPR/Cas9 gene editing and CAR T-cell therapy. CRISPR/Cas9 technology can precisely target and correct the FLT3 gene mutation responsible for AML proliferation. Simultaneously, CAR T-cell therapy harnesses the immune system to target FLT3-mutated AML cells using engineered T cells. While promising, these approaches come with challenges, such as off-target effects for CRISPR/Cas9 and complications like cytokine release syndrome for CAR T-cell therapy. Nevertheless, they offer a groundbreaking paradigm shift in AML treatment, potentially providing more effective and personalized therapies for patients with FLT3 mutations. Further research and clinical trials are essential to fully realize their potential and address associated hurdles. This combination therapy offers hope for improving outcomes in AML patients with FLT3 mutations, representing a significant advancement in precision oncology.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call